Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Impact of partial versus whole breast radiation therapy on fatigue, perceived stress, quality of life and natural killer cell activity in women with breast cancer

Authors: Kevin Albuquerque, Dina Tell, Philip Lobo, Linda Millbrandt, Herbert L Mathews, Linda Witek Janusek

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Introduction

This pilot study used a prospective longitudinal design to compare the effect of adjuvant whole breast radiation therapy (WBRT) versus partial breast radiation therapy (PBRT) on fatigue, perceived stress, quality of life and natural killer cell activity (NKCA) in women receiving radiation after breast cancer surgery.

Methods

Women (N = 30) with early-stage breast cancer received either PBRT, Mammosite brachytherapy at dose of 34 Gy 10 fractions/5 days, (N = 15) or WBRT, 3-D conformal techniques at dose of 50 Gy +10 Gy Boost/30 fractions, (N = 15). Treatment was determined by the attending oncologist after discussion with the patient and the choice was based on tumor stage and clinical need. Women were assessed prior to initiation of radiation therapy and twice after completion of radiation therapy. At each assessment, blood was obtained for determination of NKCA and the following instruments were administered: Perceived Stress Scale (PSS), Functional Assessment of Cancer Therapy-Fatigue (FACT-F), and Functional Assessment of Cancer Therapy-General (FACT-G). Hierarchical linear modeling (HLM) was used to evaluate group differences in initial outcomes and change in outcomes over time.

Results

Fatigue (FACT-F) levels, which were similar prior to radiation therapy, demonstrated a significant difference in trajectory. Women who received PBRT reported progressively lower fatigue; conversely fatigue worsened over time for women who received WBRT. No difference in perceived stress was observed between women who received PBRT or WBRT. Both groups of women reported similar levels of quality of life (FACT-G) prior to initiation of radiation therapy. However, HLM analysis revealed significant group differences in the trajectory of quality of life, such that women receiving PBRT exhibited a linear increase in quality of life over time after completion of radiation therapy; whereas women receiving WBRT showed a decreasing trajectory. NKCA was also similar between therapy groups but additional post hoc analysis revealed that better quality of life significantly predicted higher NKCA regardless of therapy.

Conclusions

Compared to WBRT, PBRT results in more rapid recovery from cancer-related fatigue with improved restoration of quality of life after radiation therapy. Additionally, better quality of life predicts higher NKCA against tumor targets, emphasizing the importance of fostering quality of life for women undergoing adjuvant radiation therapy.
Appendix
Available only for authorised users
Literature
1.
Vicini FA, Baglan KL, Kestin LL, Mitchell C, Chen PY, Frazier RC, Edmundson G, Goldstein NS, Benitez P, Huang RR, et al: Accelerated treatment of breast cancer. J Clin Oncol. 2001, 19 (7): 1993-2001.PubMed
2.
King TA, Bolton JS, Kuske RR, Fuhrman GM, Scroggins TG, Jiang XZ: Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T(is,1,2) breast cancer. Am J Surg. 2000, 180 (4): 299-304. 10.1016/S0002-9610(00)00454-2.CrossRefPubMed
3.
Polgar C, Sulyok Z, Fodor J, Orosz Z, Major T, Takacsi-Nagy Z, Mangel LC, Somogyi A, Kasler M, Nemeth G: Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial. J Surg Oncol. 2002, 80 (3): 121-128. 10.1002/jso.10110. discussion 129CrossRefPubMed
4.
Kuerer HM, Julian TB, Strom EA, Lyerly HK, Giuliano AE, Mamounas EP, Vicini FA: Accelerated partial breast irradiation after conservative surgery for breast cancer. Ann Surg. 2004, 239 (3): 338-351. 10.1097/01.sla.0000114219.71899.13.CrossRefPubMedPubMedCentral
5.
Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, Julian TB, Marks LB, Todor DA, Vicini FA, et al: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009, 74 (4): 987-1001. 10.1016/j.ijrobp.2009.02.031.CrossRefPubMed
6.
A Randomized Phase III Study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clin Adv Hematol Oncol. 2006, 4 (10): 719-721.
7.
Berger AM, Visovsky C, Hertzog M, Holtz S, Loberiza FR: Usual and Worst Symptom Severity and Interference With Function in Breast Cancer Survivors. J Support Oncol. 2012, 10 (3): 112-118. 10.1016/j.suponc.2011.11.001.CrossRefPubMed
8.
Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR: Cancer-related fatigue: the scale of the problem. Oncologist. 2007, 12 (Suppl 1): 4-10.CrossRefPubMed
9.
10.
Schmidt M, Chang-Claude J, Vrieling A, Heinz J, Flesch-Janys D, Steindorf K: Fatigue and quality of life in breast cancer survivors: temporal courses and long-term pattern. J Cancer Surviv. 2012, 6 (1): 11-19. 10.1007/s11764-011-0197-3.CrossRefPubMed
11.
Andrykowski MA, Donovan KA, Laronga C, Jacobsen PB: Prevalence, predictors, and characteristics of off-treatment fatigue in breast cancer survivors. Cancer. 2010, 116 (24): 5740-5748. 10.1002/cncr.25294.CrossRefPubMedPubMedCentral
12.
Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR: Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000, 18 (4): 743-753.PubMed
13.
Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer. 2006, 106 (4): 751-758. 10.1002/cncr.21671.CrossRefPubMed
14.
Taunk NK, Haffty BG, Chen S, Khan AJ, Nelson C, Pierce D, Goyal S: Comparison of radiation-induced fatigue across 3 different radiotherapeutic methods for early stage breast cancer. Cancer. 2011, 117 (18): 4116-4124. 10.1002/cncr.26013.CrossRefPubMed
15.
Dhruva A, Dodd M, Paul SM, Cooper BA, Lee K, West C, Aouizerat BE, Swift PS, Wara W, Miaskowski C: Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy. Cancer Nurs. 2010, 33 (3): 201-212. 10.1097/NCC.0b013e3181c75f2a.CrossRefPubMedPubMedCentral
16.
Wagner LI, Cella D: Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004, 91 (5): 822-828.PubMedPubMedCentral
17.
Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997, 34 (3 Suppl 2): 4-12.PubMed
18.
Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT: Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat. 2007, 105 (2): 209-219. 10.1007/s10549-006-9447-x.CrossRefPubMed
19.
Lee ES, Lee MK, Kim SH, Ro JS, Kang HS, Kim SW, Lee KS, Yun YH: Health-Related Quality of Life in Survivors With Breast Cancer 1 Year After Diagnosis Compared With the General Population: A Prospective Cohort Study. Ann Surg. 2011, 253 (1): 101-108. 10.1097/SLA.0b013e3181f662ce. 110.1097/SLA.1090b1013e3181f1662ceCrossRefPubMed
20.
Cavalli Kluthcovsky A, Urbanetz A, de Carvalho D, Pereira Maluf E, Schlickmann Sylvestre G, Bonatto Hatschbach S: Fatigue after treatment in breast cancer survivors: prevalence, determinants and impact on health-related quality of life. Support Care Cancer. 2011, Oct 13. [Epub ahead of print] PMID: 21994001
21.
Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson A, Ridsdale L: The hidden cost of chronic fatigue to patients and their families. BMC Health Serv Res. 2010, 10 (1): 56-63. 10.1186/1472-6963-10-56.CrossRefPubMedPubMedCentral
22.
Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, Cole S, Aziz N: Inflammatory Biomarkers and Fatigue during Radiation Therapy for Breast and Prostate Cancer. Clin Cancer Res. 2009, 15 (17): 5534-5540. 10.1158/1078-0432.CCR-08-2584.CrossRefPubMedPubMedCentral
23.
Witek-Janusek L, Gabram S, Mathews HL: Psychologic stress, reduced NK cell activity, and cytokine dysregulation in women experiencing diagnostic breast biopsy. Psychoneuroendocrinology. 2007, 32 (1): 22-35. 10.1016/j.psyneuen.2006.09.011.CrossRefPubMed
24.
Witek-Janusek L, Albuquerque K, Chroniak KR, Chroniak C, Durazo-Arvizu R, Mathews HL: Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav Immun. 2008, 22 (6): 969-981. 10.1016/j.bbi.2008.01.012.CrossRefPubMedPubMedCentral
25.
Thornton LM, Andersen BL, Crespin TR, Carson WE: Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun. 2007, 21 (2): 185-194. 10.1016/j.bbi.2006.06.007.CrossRefPubMed
26.
Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, et al: Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest. 2003, 111 (8): 1161-1170.CrossRefPubMedPubMedCentral
27.
Street SE, Cretney E, Smyth MJ: Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001, 97 (1): 192-197. 10.1182/blood.V97.1.192.CrossRefPubMed
28.
Diefenbach A, Raulet DH: The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002, 188: 9-21. 10.1034/j.1600-065X.2002.18802.x.CrossRefPubMed
29.
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 2011, 331 (6013): 44-49. 10.1126/science.1198687.CrossRefPubMedPubMedCentral
30.
Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998, 95 (13): 7556-7561. 10.1073/pnas.95.13.7556.CrossRefPubMedPubMedCentral
31.
Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD: An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med. 1998, 188 (9): 1611-1619. 10.1084/jem.188.9.1611.CrossRefPubMedPubMedCentral
32.
Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA: Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 1999, 162 (11): 6658-6662.PubMed
33.
van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H: Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996, 184 (5): 1781-1790. 10.1084/jem.184.5.1781.CrossRefPubMed
34.
Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ: Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 2003, 63 (1): 207-213.PubMed
35.
Lutgendorf S, Costanzo E, Siegel S: Psychosocial influences in oncology: An expanded model of biobehavioral mechanisms. Psychoneuroimmunology. Edited by: Ader R. 2007, Elsevier Academic Press, Burlington, MA, 869-895. Fourth ednCrossRef
36.
Avraham R, Ben-Eliyahu S: Neuroendocrine regulation of cancer progression: II. Immunological mechanisms, clinical relevance, and prophylactic measures. Psychoneuroimmunology. Edited by: Ader R. 2007, Elsevier Academic Press, Burlington, MA, 251-265. Fourth ednCrossRef
37.
Stojanovic A, Cerwenka A: Natural killer cells and solid tumors. J Innate Immun. 2011, 3 (4): 355-364. 10.1159/000325465.CrossRefPubMed
38.
Ben-Eliyahu S: The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav Immun. 2003, 17 (Suppl 1): S27-36.CrossRefPubMed
39.
Mellios T, Ko HL, Beuth J: Impact of adjuvant chemo- and radiotherapy on the cellular immune system of breast cancer patients. In Vivo. 2010, 24 (2): 227-230.PubMed
40.
Koukourakis GV, Zabatis H, Zacharias GA, Koukourakis MJ: Post-surgical irradiation causes cellular immune suppression in patients with breast cancer. Eur J Cancer Care (Engl). 2009, 18 (3): 306-312. 10.1111/j.1365-2354.2008.00995.x.CrossRef
41.
Dalesio V, Pacelli R, Durante M, Canale Cama G, Cella L, Gialanella G, Grossi G, Pugliese M, Punzo G, Sardi I, et al: Lymph nodes in the irradiated field influence the yield of radiation-induced chromosomal aberrations in lymphocytes from breast cancer patients. Int J Radiat Oncol Biol Phys. 2003, 57 (3): 732-738. 10.1016/S0360-3016(03)00664-3.CrossRef
42.
Bar Ad V: Accelerated partial breast irradiation- pros and cons. Rev Recent Clin Trials. 2011, 6 (1): 1-6. 10.2174/157488711793980183.CrossRefPubMed
43.
Belkacemi Y, Chauvet MP, Giard S, Villette S, Lacornerie T, Bonodeau F, Baranzelli MC, Bonneterre J, Lartigau E: Partial breast irradiation as sole therapy for low risk breast carcinoma: early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase II study. Radiother Oncol. 2009, 90 (1): 23-29. 10.1016/j.radonc.2008.06.004.CrossRefPubMed
44.
Vicini FA, Beitsch PD, Quiet CA, Keleher A, Garcia D, Snider HC, Gittleman MA, Zannis VJ, Kuerer H, Whitacre EB, et al: First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer. 2005, 104 (6): 1138-1148. 10.1002/cncr.21289.CrossRefPubMed
45.
Keisch M, Vicini F, Kuske RR, Hebert M, White J, Quiet C, Arthur D, Scroggins T, Streeter O: Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003, 55 (2): 289-293. 10.1016/S0360-3016(02)04277-3.CrossRefPubMed
46.
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997, 13 (2): 63-74. 10.1016/S0885-3924(96)00274-6.CrossRefPubMed
47.
Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Soc Behav. 1983, 24 (4): 385-396. 10.2307/2136404.CrossRefPubMed
48.
Cohen S, Williamson G: Perceived stress in a probability sample of the United States. The social psychology of health: Claremont Symposium on applied social psychology. Edited by: Spacapan S, Oskamp S. 1988, Sage, Newbury Park, CA, 31-67.
49.
Nagabhushan M, Mathews HL, Witek-Janusek L: Aberrant nuclear expression of ap-1 and nfkb in lymphocytes of women stressed by the experience of breast biopsy. Brain Behav Immun. 2001, 15 (1): 78-84. 10.1006/brbi.2000.0589.CrossRefPubMed
50.
Raudenbush SW, Bryk AS: Hierarchical linear models: Applications and data analysis methods. 2002, Sage Publications, Thousand Oaks, CA, 2
51.
Smith GL, Xu Y, Buchholz TA, Giordano SH, Jiang J, Shih YC, Smith BD: Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. J Amer Med Assoc. 2012, 307 (17): 1827-1837. 10.1001/jama.2012.3481.CrossRef
52.
Husain ZA, Mahmood U, Hanlon A, Neuner G, Buras R, Tkaczuk K, Feigenberg SJ: Accelerated partial breast irradiation via brachytherapy: a patterns-of-care analysis with ASTRO consensus statement groupings. Brachytherapy. 2011, 10 (6): 479-485. 10.1016/j.brachy.2011.05.001.CrossRefPubMed
53.
Dekhne N, Shah C, Wilkinson JB, Mitchell C, Chen P, Margolis J, Vicini F: Axillary lymph node failure in patients treated with accelerated partial breast irradiation. Cancer. 2012, 118 (1): 38-43. 10.1002/cncr.26305.CrossRefPubMed
54.
Hattangadi JA, Taback N, Neville BA, Harris JR, Punglia RS: Accelerated Partial Breast Irradiation Using Brachytherapy for Breast Cancer: Patterns in Utilization and Guideline Concordance. J Natl Cancer Inst. 2011, 104 (1): 1-13.
55.
Smith GL, Xu Y, Buchholz TA, Giordano SH, Smith BD: Partial Breast Brachytherapy Is Associated with Inferior Effectiveness and Increased Toxicity Compared with Whole Breast Irradiation in Older Patients. Cancer Res. 2011, 71 (24 Suppl.): abstract S2-1-CrossRef
56.
Wratten C, Kilmurray J, Nash S, Seldon M, Hamilton CS, O'Brien PC, Denham JW: Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys. 2004, 59 (1): 160-167. 10.1016/j.ijrobp.2003.10.008.CrossRefPubMed
57.
Von Ah DM, Kang DH, Carpenter JS: Predictors of cancer-related fatigue in women with breast cancer before, during, and after adjuvant therapy. Cancer Nurs. 2008, 31 (2): 134-144. 10.1097/01.NCC.0000305704.84164.54.CrossRefPubMed
58.
Andrykowski MA, Donovan KA, Jacobsen PB: Magnitude and correlates of response shift in fatigue ratings in women undergoing adjuvant therapy for breast cancer. J Pain Symptom Manage. 2009, 37 (3): 341-351. 10.1016/j.jpainsymman.2008.03.015.CrossRefPubMed
59.
Brucker PS, Yost K, Cashy J, Webster K, Cella D: General Population and Cancer Patient Norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005, 28 (2): 192-211. 10.1177/0163278705275341.CrossRefPubMed
60.
Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE: Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales. J Pain Symptom Manage. 2002, 24 (6): 547-561. 10.1016/S0885-3924(02)00529-8.CrossRefPubMed
61.
Webster K, Cella D, Yost K: The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003, 1 (1): 79-10.1186/1477-7525-1-79.CrossRefPubMedPubMedCentral
62.
Yost KJ, Eton DT: Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences. Eval Health Prof. 2005, 28 (2): 172-191. 10.1177/0163278705275340.CrossRefPubMed
63.
Kim SH, Son BH, Hwang SY, Han W, Yang JH, Lee S, Yun YH: Fatigue and depression in disease-free breast cancer survivors: prevalence, correlates, and association with quality of life. J Pain Symptom Manage. 2008, 35 (6): 644-655. 10.1016/j.jpainsymman.2007.08.012.CrossRefPubMed
64.
Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz H-J, Nortier JWR: Epoetin Alfa Treatment Results in Clinically Significant Improvements in Quality of Life in Anemic Cancer Patients When Referenced to the General Population. J Clin Oncol. 2003, 21 (2): 366-373. 10.1200/JCO.2003.02.136.CrossRefPubMed
65.
Cella D: The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park). 2002, 16 (9 Suppl 10): 125-132.
66.
Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J: Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer. 2003, 39 (3): 335-345. 10.1016/S0959-8049(02)00628-7.CrossRefPubMed
67.
Reimer T, Gerber B: Quality-of-life considerations in the treatment of early-stage breast cancer in the elderly. Drugs Aging. 2010, 27 (10): 791-800. 10.2165/11584700-000000000-00000.CrossRefPubMed
68.
Jacobsen PB, Donovan KA, Weitzner MA: Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry. 2003, 8 (4): 229-240.PubMed
69.
70.
Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR: Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008, 26 (6): 971-982. 10.1200/JCO.2007.10.7805.CrossRefPubMedPubMedCentral
71.
Irwin MR: Inflammation at the intersection of behavior and somatic symptoms. Psychiatr Clin North Am. 2011, 34 (3): 605-620. 10.1016/j.psc.2011.05.005.CrossRefPubMed
72.
Haroon E, Raison CL, Miller AH: Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior. Neuropsychopharmacology. 2012, 37 (1): 137-162. 10.1038/npp.2011.205.CrossRefPubMed
73.
Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE: The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun. 2007, 21 (4): 413-427. 10.1016/j.bbi.2006.11.004.CrossRefPubMed
74.
Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K, Flath BC: Biomarkers of depression in cancer patients. Cancer. 2006, 107 (11): 2723-2729. 10.1002/cncr.22294.CrossRefPubMed
75.
Stone HB, Coleman CN, Anscher MS, McBride WH: Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003, 4 (9): 529-536. 10.1016/S1470-2045(03)01191-4.CrossRefPubMed
76.
Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D: Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest. 1991, 88 (2): 691-695. 10.1172/JCI115354.CrossRefPubMedPubMedCentral
77.
Seo N, Tokura Y: Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. J Interferon Cytokine Res. 1999, 19 (6): 555-561. 10.1089/107999099313686.CrossRefPubMed
78.
Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K: Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer. 1998, 83 (1): 58-63. 10.1002/(SICI)1097-0142(19980701)83:1<58::AID-CNCR8>3.0.CO;2-A.CrossRefPubMed
79.
Gonzales FM, Vargas JA, Lopez-Cortijo C, Castejon R, Forriz C, Ramirez-Camancho R, Millan F, Durantez A: Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1998, 124: 852-856.CrossRef
80.
Koda K, Saito I, Takiguchi N, Oda K, Numomura M, Nakajima N: Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas. Int Surg. 1997, 82 (2): 190-193.PubMed
81.
Nakamura H, Kawasaki N, Hagiwara M, Saito M, Konaka C, Kato H: Cellular immunologic parameters related to age, gender, and stage in lung cancer patients. Lung Cancer. 2000, 28 (2): 139-145. 10.1016/S0169-5002(99)00133-6.CrossRefPubMed
82.
Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE: Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer. 2003, 105 (5): 717-723. 10.1002/ijc.11139.CrossRefPubMed
83.
Kiecolt-Glaser JK, Robles TF, Heffner KL, Loving TJ, Glaser R: Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol. 2002, 13 (Suppl 4): 165-169. 10.1093/annonc/mdf655.CrossRefPubMed
84.
Moynihan JA: Mechanisms of stress-induced modulation of immunity. Brain Behav Immun. 2003, 17 (Suppl 1): S11-16.CrossRefPubMed
85.
Webster Marketon JI, Glaser R: Stress hormones and immune function. Cell Immunol. 2008, 252 (1–2): 16-26.CrossRefPubMed
Metadata
Title
Impact of partial versus whole breast radiation therapy on fatigue, perceived stress, quality of life and natural killer cell activity in women with breast cancer
Authors
Kevin Albuquerque
Dina Tell
Philip Lobo
Linda Millbrandt
Herbert L Mathews
Linda Witek Janusek
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-251

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Cancer incidence and mortality trends in Australian adolescents and young adults, 1982–2007

Research article

Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines

Research article

Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker

Research article

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone

Debate

Natural resistance to cancers: a Darwinian hypothesis to explain Peto’s paradox

Study protocol

Design of the study: How can health care help female breast cancer patients reduce their stress symptoms? A randomized intervention study with stepped-care
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits